VAM
RVNC

Visium Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Visium Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,115,000
Closed -$23.1M – 1314
2015
Q1 		$23.1M Buy
1,115,000
+115,000
+12% +$1.99M 0.34% 58
2014
Q4 		$16.9M Buy
+1,000,000
New +$17.5M 0.24% 77
2014
Q3 		– Sell
-362,922
Closed -$12.3M – 1262
2014
Q2 		$12.3M Sell
362,922
-535,078
-60% -$16.8M 0.19% 100
2014
Q1 		$28.3M Buy
+898,000
New +$28.1M 0.46% 44

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Visium Asset Management's RVNC Position: Q2 2015 in Review

Visium Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2015, closing a stake of 1,115,000 shares — an estimated $23.1M sold.

Visium Asset Management first reported a position in RVNC in Q1 2014 and held it in 4 quarters. The position peaked at $28.3M in Q1 2014. 88 funds tracked by Wall St. Rank hold RVNC as of Q2 2015.

  • Visium Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Visium Asset Management sold 1,115,000 Revance Therapeutics, Inc. shares in Q2 2015, an estimated $23.1M.
  • Visium Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Visium Asset Management's Revance Therapeutics, Inc. position peaked at $28.3M in Q1 2014.
  • 88 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2015.

Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.